Holen Sie sich die Stockscreener-App
0.4346
3.72%
0.0156
Schlusskurs vom Vortag:
$0.419
Offen:
$0.43
24-Stunden-Volumen:
802.78K
Relative Volume:
1.26
Marktkapitalisierung:
$24.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-20.23M
KGV:
-0.7736
EPS:
-0.5618
Netto-Cashflow:
$-13.97M
1W Leistung:
+20.79%
1M Leistung:
-3.44%
6M Leistung:
-63.17%
1J Leistung:
-74.73%
1-Tages-Spanne:
$0.4218
$0.454
1-Wochen-Bereich:
$0.3584
$0.454
52-Wochen-Spanne:
$0.355
$4.00
Heartbeam Inc Stock (BEAT) Company Profile
Firmenname
Heartbeam Inc
Sektor
Branche
Telefon
408-899-4443
Adresse
2118 WALSH AVE., SUITE 210, SANTA CLARA
Compare BEAT vs VEEV, TEM, TXG, BTSG, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
0.4346 | 20.27M | 0 | -20.23M | -13.97M | -0.5618 |
VEEV
Veeva Systems Inc
|
273.33 | 45.44B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
76.63 | 15.43B | 1.36B | -302.91M | -219.93M | -1.7182 |
TXG
10 X Genomics Inc
|
93.50 | 11.17B | 638.78M | -22.66M | 122.18M | -0.1744 |
BTSG
Brightspring Health Services Inc
|
60.25 | 11.20B | 13.65B | 169.86M | 412.12M | 1.0758 |
HNGE
Hinge Health Inc
|
97.67 | 7.71B | 646.34M | -512.40M | 202.76M | -6.6871 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2026-03-31 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-27 | Eingeleitet | D. Boral Capital | Buy |
| 2026-03-16 | Herabstufung | The Benchmark Company | Buy → Speculative Buy |
| 2025-12-11 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2025-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-31 | Eingeleitet | Roth Capital | Buy |
| 2020-09-11 | Eingeleitet | Needham | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-04-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-07-26 | Bestätigt | Lake Street | Buy |
| 2018-04-26 | Bestätigt | The Benchmark Company | Buy |
| 2018-02-23 | Bestätigt | Dougherty & Company | Buy |
| 2017-11-08 | Bestätigt | Dougherty & Company | Buy |
| 2017-10-26 | Eingeleitet | Raymond James | Outperform |
| 2017-10-24 | Eingeleitet | SunTrust | Buy |
| 2017-08-09 | Bestätigt | Dougherty & Company | Buy |
| 2017-07-19 | Bestätigt | The Benchmark Company | Buy |
| 2017-04-11 | Bestätigt | Dougherty & Company | Buy |
| 2016-12-02 | Eingeleitet | Dougherty & Company | Buy |
| 2016-09-13 | Eingeleitet | Sidoti | Buy |
| 2016-08-03 | Bestätigt | The Benchmark Company | Buy |
| 2015-07-28 | Bestätigt | Dougherty & Company | Buy |
| 2013-10-24 | Eingeleitet | The Benchmark Company | Buy |
| 2013-08-21 | Eingeleitet | Dougherty & Company | Buy |
Alle ansehen
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
HEARTBEAM, INC. : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY - webull.com
H.C. Wainwright Maintains HeartBeam(BEAT.US) With Hold Rating - Moomoo
HeartBeam Granted New U.S. Patent Expanding Acoustic Sensing for its ECG Device - Medical Product Outsourcing
HeartBeam (BEAT) Shifts Focus to Myocardial Infarction Detection Amid Commercialization Challenges - GuruFocus
HeartBeam shifts focus to heart attack detection technology - Investing.com
HeartBeam shifts focus to heart attack detection technology By Investing.com - Investing.com Canada
HeartBeam, Inc. Letter to Shareholders - Yahoo Finance
HeartBeam’s Heart Attack Detection Study Enrollment Completed - Medical Product Outsourcing
Heartbeam Inc. Warrant (BEATW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
BEATW Form 4 FilingsHeartbeam, Inc. Warrant SEC Form 4 - Stock Titan
Heartbeam Inc (BEAT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Heartbeam Inc. Warrant (BEATW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Heartbeam Inc. Warrant (BEATW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Heartbeam Inc. Warrant (BEATW) Peer Comparison – Compare with Others - Value Research
Heartbeam Warrant (BEATW) Plunges 32% to $0.01 as Support and Resistance Converge at Penny LevelsWyckoff Accumulation - dars.gov.et
Heartbeam Inc (BEAT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Heartbeam Warrant (BEATW) Plunges 32% to $0.01 as Speculative Value EvaporatesLinear Regression - careplusvn.com
Heartbeam (BEATW) Today: Ends Lower by 26.67% at $0.01; Traders Can Monitor the $0.01-$0.01 Range in the Latest SessionLong Short Pair - vinanet.vn
Heartbeam (BEATW) Update: Closes with Little Net Change at $0.01 in the Latest Reading; Price Setup - vinanet.vn
Heartbeam (BEAT) Shares: Finishes 0.93% Lower at $0.48 for the Current Session; Immediate View - vinanet.vn
Price to earnings forward of Heartbeam, Inc. – BOATS:BEATW - TradingView
HeartBeam Q2 net loss hits USD 5M - Medical Buyer
Heartbeam Inc (BEAT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K Heartbeam Inc For: 14 August - Investing.com India
HeartBeam enters $25 million at-the-market equity sales agreement with Titan Partners - Investing.com Nigeria
Form 8K Heartbeam Inc For: 14 August By Investing.com - Investing.com Australia
Heartbeam, Inc. Enters Into At-The-Market Equity Offering Sales Agreement For Up To $25 Million In Common Stock - TradingView
Medical Journal Article Highlights Technology’s Potential to Detect Heart Attack Risk at Home - Medical Product Outsourcing
Heartbeam Inc. (BEAT) Slides 7.2% to $0.55 as Selling Pressure MountsVolatility Term Structure - Vinanet
HeartBeam, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Heartbeam Warrant (BEATW) Slides 3.6% as Shares Trade at Penny LevelsMESA MA - vinanet.vn
HeartBeam wins U.S. patent for acoustic sensing, impedance - scanx.trade
HeartBeam Inc (BEAT) (Q2 2026) Earnings Call Highlights: FDA Submission Advances and Commercial ... - Investing.com Canada
Heartbeam earnings missed by $1.01, revenue fell short of estimates - Investing.com Canada
HeartBeam posts wider Q2 loss than expected, shares inch lower - Investing.com
HeartBeam Q2 slides show clinical progress despite wider Q2 2026 loss By Investing.com - Investing.com India
HeartBeam Q2 slides show clinical progress despite wider Q2 2026 loss - Investing.com
Why is Heartbeam stock sliding today? By Investing.com - Investing.com India
Earnings call transcript: HeartBeam stock slips after hours following Q2 results - Investing.com
BEAT: FDA pre-submission for heart attack detection and commercial rollout drive growth, with costs down - TradingView
HeartBeam Q2 Results: Net loss narrows to $5M, cash burn down 7% - scanx.trade
Transcript : HeartBeam, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
BEAT: FDA pre-submission completed, commercial rollout expands, and cash runway extended into 2027 - TradingView
HeartBeam posts wider Q2 loss than expected, shares inch lower By Investing.com - Investing.com Nigeria
HeartBeam Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Why is Heartbeam stock sliding today? - Investing.com
HeartBeam, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BEAT) 2026-08-13 - Seeking Alpha
HeartBeam, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
HeartBeam (BEAT): Strome group details 6.8% ownership and July–August share sales - Stock Titan
HeartBeam Q2 2026 results: Cash-burn outlook improves as net loss holds near $5 million - TradingKey
Finanzdaten der Heartbeam Inc-Aktie (BEAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Heartbeam Inc-Aktie (BEAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Elfrink Willem | Director |
Apr 16 '26 |
Buy |
0.80 |
187,500 |
150,000 |
538,667 |
| JAFF MICHAEL R | Director |
Apr 16 '26 |
Buy |
0.80 |
31,250 |
25,000 |
31,250 |
| Vajdic Branislav | Director |
Apr 16 '26 |
Buy |
0.80 |
31,250 |
25,000 |
909,914 |
| Ferrari Richard | Director |
Apr 16 '26 |
Buy |
0.80 |
62,500 |
50,000 |
291,636 |
| ENO Robert Paul | President |
Apr 16 '26 |
Buy |
0.80 |
12,500 |
10,000 |
36,742 |
| Ortigas-Wedekind Marga | Director |
Apr 16 '26 |
Buy |
0.80 |
25,000 |
20,000 |
137,293 |
| STROME MARK E | Director |
Apr 16 '26 |
Buy |
0.80 |
750,000 |
600,000 |
3,650,000 |
| STROME MARK E | 10% Owner |
Dec 17 '25 |
Sale |
3.58 |
250,000 |
895,000 |
2,900,000 |
| de Urioste George | Director |
Dec 18 '25 |
Sale |
2.83 |
33,185 |
93,914 |
0 |
| de Urioste George | Director |
Dec 17 '25 |
Sale |
3.68 |
23,961 |
88,176 |
33,185 |
0.13%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):